Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding

Nov 22 2011

• By Paul Bonanos

Related Content

Portola Marries Factor Xa Clot Buster Off To Merck

Jul 09 2009

Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis

Feb 12 2009

Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

Nov 04 2011

Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?

Sep 05 2011

Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban

Sep 30 2011

Back To The Drawing Board For Portola After Merck Returns Betrixaban

Mar 24 2011

Related Companies

Merck & Co., Inc.

Portola Pharmaceuticals, Inc.

Bayer AG

Johnson & Johnson

Boehringer Ingelheim GmbH

Bristol Myers Squibb Company

Pfizer Inc.

Astellas Pharma, Inc.

Takeda Pharmaceutical Co. Ltd.

Biogen, Inc.

Novartis AG

Additional Topics

United States Asia Pacific Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window